Karl Swedberg professeur suédois
Swedberg, Karl
Swedberg, Karl (medycyna).
Swedberg, Karl, 1944-
VIAF ID: 56866011 (Personal)
Permalink: http://viaf.org/viaf/56866011
Preferred Forms
-
100 0 _
‡a
Karl Swedberg
‡c
professeur suédois
-
200 _ |
‡a
Swedberg
‡b
Karl
-
200 _ 1 ‡a Swedberg ‡b Karl ‡f 1944-
-
100 1 _ ‡a Swedberg, Karl
-
100 1 _
‡a
Swedberg, Karl
-
100 1 _ ‡a Swedberg, Karl
-
100 1 _
‡a
Swedberg, Karl
‡c
(medycyna)
-
100 1 _ ‡a Swedberg, Karl ‡c (medycyna).
-
100 1 _ ‡a Swedberg, Karl, ‡d 1944-
4xx's: Alternate Name Forms (7)
Works
| Title | Sources |
|---|---|
| Congestiv cardiomyopati : en klinisk studie med särskild hänsyn till noninvasiv teknik och behandling med betareceptorblockad |
|
| Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations |
|
| Ethics in human research: when is clinical practice research? |
|
| The Evolving Role of Angiotensin Receptor Blockade in Cardiovascular Disease : Montreux, Switzerland, 24-25 April, 2004 |
|
| Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology |
|
| Expert consensus document on beta-adrenergic receptor blockers |
|
| Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial |
|
| Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). |
|
| Fatigue is a prevalent and severe symptom associated with uncertainty and sense of coherence in patients with chronic heart failure |
|
| Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis |
|
| Göteborg Metoprolol Trial: enzyme-estimated infarct size. |
|
| Göteborg Metoprolol Trial: mortality and causes of death. |
|
| Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). |
|
| HEAAL: the final chapter in the story of angiotensin receptor blockers in heart failure--lessons learnt from a decade of trials |
|
| Health-care improvements in a financially constrained environment |
|
| Health-Related Quality of Life Outcomes in PARADIGM-HF. |
|
| Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden |
|
| Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum |
|
| Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis |
|
| Heart-lung radiography after myocardial infarction is of insignificant value for the estimation of prognosis |
|
| Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties |
|
| Heart rate reduction in cardiovascular disease and therapy |
|
| Hemodynamic effects of the cardioselective beta-blocking agent metoprolol in acute myocardial infarction. A 24-hour catheterization study. |
|
| Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes |
|
| Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group |
|
| Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations |
|
| Impact of device-guided slow breathing on symptoms of chronic heart failure: a randomized, controlled feasibility study |
|
| Impacts of patient characteristics on hospital care experience in 34,000 Swedish patients |
|
| Implantable Cardioverter-Defibrillators in Patients Hospitalized for Heart Failure With Chronically Reduced Left Ventricular Ejection Fraction |
|
| Implementation of device therapy |
|
| Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF). |
|
| Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator |
|
| Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT‐proBNP Guided Management of Heart Failure – SIGNAL‐HF (Swedish Intervention study – Guidelines and NT‐proBNP AnaLysis in Heart Failure) |
|
| Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: result |
|
| Increased plasma levels of atrial natriuretic peptide in patients with congestive heart failure |
|
| Increased rate of evolution of QRS changes in patients with acute myocardial infarction. Results from the Vermut Study |
|
| Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease |
|
| Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases |
|
| Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome |
|
| Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients |
|
| Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial |
|
| Influence of Sacubitril/Valsartan |
|
| International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction |
|
| International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey |
|
| Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance. |
|
| Is creatine supplementation helpful for patients with chronic heart failure? |
|
| Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence? |
|
| Is neurohormonal activation a major determinant of the response to ACE inhibition in left ventricular dysfunction and heart failure? |
|
| Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study |
|
| Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. |
|
| Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction |
|
| Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial |
|
| Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program |
|
| Long delay outside hospitals makes effective treatment of acute myocardial infarction worse |
|
| Tailoring heart failure therapy, 2003: |
|
